Few conditions push regenerative medicine to its limits the way amyotrophic lateral sclerosis — ALS, or Lou Gehrig's disease — does. The hallmark of ALS is the progressive death of motor neurons in the brain and spinal cord, and once those neurons are lost, no current therapy reliably brings them back. Families understandably search for anything that might slow the decline. The honest job of a regenerative clinic is to set out clearly what cellular therapy can — and cannot — do in this setting.

What is happening at the cellular level in ALS?

ALS is a heterogeneous disease with multiple known biological drivers, and important features that recur across most cases include:

This list matters because it tells you where any therapy can plausibly help — and where it cannot. No current intervention reverses motor neuron loss once it has occurred. What is potentially modifiable is the microenvironment in which the surviving neurons are still trying to function.

What MSCs may biologically contribute

Mesenchymal Stem Cells do not become motor neurons. They are not designed to. What they do — and the reason research interest in MSC therapy for ALS continues — is alter the cellular environment around stressed neurons. Their relevant actions in ALS biology include:

Anti-inflammatory signalling

MSCs reduce activity of pro-inflammatory microglia and shift astrocyte populations toward less neurotoxic states. The chronic neuroinflammation in ALS is one of the few targets we have, and it is the primary mechanism by which MSC therapy is hypothesised to slow progression.

Neurotrophic support

MSCs secrete factors such as BDNF, GDNF, NGF, and VEGF that support the survival of stressed but still-living motor neurons. The goal is not to revive lost neurons but to give vulnerable surviving neurons a less hostile environment.

Mitochondrial support

Emerging research shows MSCs can transfer healthy mitochondria to neighbouring cells via tunneling nanotubes — a mechanism with particular relevance in a disease where mitochondrial failure is a recognised feature.

Oxidative stress reduction

MSC paracrine signalling improves the redox environment around stressed cells, modestly reducing one of the drivers of neuronal death.

Clinical setting for intravenous MSC infusion in regenerative medicine
MSC delivery in ALS protocols typically combines intravenous and (in some research settings) intrathecal routes — depending on the indication, dose, and clinical safety review.

What the evidence supports — and what it doesn't

An honest summary of the published research landscape:

What is plausible: A modest reduction in the slope of decline (e.g. measured by the ALSFRS-R functional rating scale) in some patients, particularly those treated earlier in the disease course. This is consistent with what MSC immunomodulation could realistically achieve. It is not a cure. It is not a reversal.

What is not supported: Restoration of lost function, return of strength to muscles already paralysed, halt of disease progression, or extension of life by years. Any clinic claiming these outcomes is overstating what biology and current research can deliver.

What remains under active investigation: Optimal cell source (Wharton's jelly vs bone marrow), route of delivery (IV alone vs IV plus intrathecal), dosing schedules, and patient selection criteria. ALS is a heterogeneous disease and the field has not yet identified which subtypes respond best.

A Hard but Important Distinction

MSC therapy for ALS is, at present, an adjunctive protocol — a possible addition to standard neurological care, not a replacement for it. The standard medications, multi-disciplinary clinic care, respiratory and nutritional support, and supportive rehabilitation that ALS patients receive remain the primary care framework. Regenerative therapy is best considered alongside that framework, not instead of it.

Who is most likely to benefit?

Within the boundaries of what is realistic, the patients with the strongest case for considering MSC therapy in ALS are those who:

Patients with very advanced ALS — already ventilator-dependent, severe bulbar involvement, or near end of expected disease course — are far less likely to see meaningful benefit from any regenerative protocol. A reputable clinic will say this clearly.

What treatment looks like

An ALS-focused MSC programme at a regulated clinical centre typically involves:

  1. Comprehensive neurological assessment in coordination with the patient's existing ALS clinic — current ALSFRS-R, FVC, neurological examination, recent MRI/EMG, medication review
  2. Inflammatory and metabolic biomarker baseline — CRP, IL-6, TNF-α, oxidative stress markers, neurofilament light chain where available
  3. Personalised protocol — typically a series of intravenous MSC infusions across 8–12 weeks, with optional intrathecal delivery in selected cases under additional safety review
  4. Continued coordination with the primary neurology team — MSC therapy supplements, never replaces, ALS clinic care
  5. Structured outcome tracking — repeat ALSFRS-R, FVC, biomarker panels at the 1, 3, 6, and 12-month milestones

Realistic expectations

Slope Possible modest change in decline rate (ALSFRS-R)
↓ Inflam. Reduction in measurable inflammatory markers
Quality Some reports of fatigue, sleep, and energy improvement

Even where a measurable signal exists, the magnitude of effect in MSC-for-ALS research is generally modest, variable across patients, and not guaranteed in any individual. That honesty is part of what separates regulated regenerative medicine from clinics that promise more than biology can deliver.

The right question for an ALS family considering MSC therapy is not "will this cure us?" — biology cannot answer yes. It is "is this a reasonable adjunct to my current ALS care, given my disease stage, and what does honest evidence say about expected magnitude of benefit?" That question has a real answer, and it should be answered before any treatment commitment.

— VELAR Clinical Team

The VELAR approach to ALS

ALS protocols at VELAR Center are designed in coordination with each patient's existing neurology and ALS clinic team — never as a replacement for that care. Each programme uses clinical-grade Wharton's jelly–derived MSCs (≥95% identity verification, >90% post-thaw viability) delivered via personalised intravenous infusion across a structured cycle, paired with comprehensive biomarker tracking and validated functional outcome scales (ALSFRS-R, FVC) at scheduled milestones.

For families in the painful position of researching options after an ALS diagnosis, our consultations focus on three questions: where are you in the disease course, what does honest current evidence support for someone in your position, and is regenerative therapy a sensible addition to the care you already have? Those answers — not a sales pitch — should drive any treatment decision.